Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary StaR® technology and structure-based drug design (SBDD) capabilities are enabling us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple pipeline and technology partners including Allergan, AstraZeneca, Daiichi Sankyo, Kymab, Morphosys, PeptiDream and Pfizer.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

Sep 18, 2018

Sosei Provides Update on HTL0018318

Jun 4, 2018
Sosei Announces Appointment of Chris Cargill as Interim CFO

Nov 11-13, 2018
Protein Structure Determination in Industry
Versailles, France
Andy Dore

© 2012-2018 Heptares Therapeutics